Mayinglong Pharmaceutical Group Co Ltd (SHG:600993) — Market Cap & Net Worth
Market Cap & Net Worth: Mayinglong Pharmaceutical Group Co Ltd (600993)
Mayinglong Pharmaceutical Group Co Ltd (SHG:600993) has a market capitalization of $1.43 Billion (CN¥9.77 Billion) as of September 21, 2026. Listed on the SHG stock exchange, this China-based company holds position #7458 globally and #1631 in its home market, demonstrating a 0.76% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mayinglong Pharmaceutical Group Co Ltd's stock price CN¥22.67 by its total outstanding shares 431053891 (431.05 Million). Also see 600993 current and non-current assets for a full breakdown of the balance sheet.
Mayinglong Pharmaceutical Group Co Ltd Market Cap History: 2015 to 2026
Mayinglong Pharmaceutical Group Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $1.27 Billion to $1.43 Billion (1.73% CAGR). Also see 600993 cash flow conversion for how efficiently the company converts equity into cash flow.
Mayinglong Pharmaceutical Group Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mayinglong Pharmaceutical Group Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 600993 stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.46x
Mayinglong Pharmaceutical Group Co Ltd's market cap is 0.46 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.04x
Mayinglong Pharmaceutical Group Co Ltd's market cap is 3.04 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.16 Billion | $2.10 Billion | $250.24 Million | 0.55x | 4.63x |
| 2017 | $1.20 Billion | $1.75 Billion | $320.05 Million | 0.68x | 3.75x |
| 2018 | $797.62 Million | $2.20 Billion | $176.21 Million | 0.36x | 4.53x |
| 2019 | $1.05 Billion | $2.71 Billion | $359.97 Million | 0.39x | 2.91x |
| 2020 | $1.22 Billion | $2.79 Billion | $419.06 Million | 0.44x | 2.91x |
| 2021 | $1.76 Billion | $3.39 Billion | $464.59 Million | 0.52x | 3.79x |
| 2022 | $1.41 Billion | $3.53 Billion | $478.57 Million | 0.40x | 2.94x |
| 2023 | $1.53 Billion | $3.14 Billion | $443.25 Million | 0.49x | 3.44x |
| 2024 | $1.65 Billion | $3.73 Billion | $528.09 Million | 0.44x | 3.12x |
| 2025 | $1.77 Billion | $3.87 Billion | $581.49 Million | 0.46x | 3.04x |
Competitor Companies of 600993 by Market Capitalization
Companies near Mayinglong Pharmaceutical Group Co Ltd in the global market cap rankings as of September 21, 2026. Review 600993 goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Mayinglong Pharmaceutical Group Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #612 globally with a market cap of $44.88 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #612 | GALDERMA GROUP AG | NYSE:GALDY | $44.88 Billion | $38.49 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Mayinglong Pharmaceutical Group Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Mayinglong Pharmaceutical Group Co Ltd's market cap moved from $1.27 Billion to $ 1.43 Billion, with a yearly change of 1.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.43 Billion | -19.04% |
| 2025 | CN¥1.77 Billion | +7.24% |
| 2024 | CN¥1.65 Billion | +7.98% |
| 2023 | CN¥1.53 Billion | +8.45% |
| 2022 | CN¥1.41 Billion | -20.17% |
| 2021 | CN¥1.76 Billion | +44.29% |
| 2020 | CN¥1.22 Billion | +16.44% |
| 2019 | CN¥1.05 Billion | +31.45% |
| 2018 | CN¥797.62 Million | -33.48% |
| 2017 | CN¥1.20 Billion | +3.55% |
| 2016 | CN¥1.16 Billion | -8.51% |
| 2015 | CN¥1.27 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 21st, 2026 the market cap of Mayinglong Pharmaceutical Group Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.43 Billion USD |
| MoneyControl | $1.43 Billion USD |
| MarketWatch | $1.43 Billion USD |
| marketcap.company | $1.43 Billion USD |
| Reuters | $1.43 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mayinglong Pharmaceutical Group Co Ltd
Mayinglong Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells Chinese and Western medicines in China and internationally. It operates through three segments: Pharmaceutical Manufacturing; Pharmaceutical Wholesale and Retail; and Medical Services. The company offers functional cosmetics, care products and food, Chinese herbal medicines, and medical devices. It a… Read more